- Home
- IMKTA vs IMNM Comparison
IMKTA vs IMNM Comparison
Compare IMKTA & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMKTA
- IMNM
- Stock Information
- Founded
- IMKTA 1963
- IMNM 2006
- Country
- IMKTA United States
- IMNM United States
- Employees
- IMKTA N/A
- IMNM N/A
- Industry
- IMKTA Food Chains
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- IMKTA Consumer Staples
- IMNM Health Care
- Exchange
- IMKTA Nasdaq
- IMNM Nasdaq
- Market Cap
- IMKTA 1.4B
- IMNM 1.2B
- IPO Year
- IMKTA N/A
- IMNM 2020
- Fundamental
- Price
- IMKTA $77.13
- IMNM $18.67
- Analyst Decision
- IMKTA
- IMNM Strong Buy
- Analyst Count
- IMKTA 0
- IMNM 8
- Target Price
- IMKTA N/A
- IMNM $25.75
- AVG Volume (30 Days)
- IMKTA 101.1K
- IMNM 1.4M
- Earning Date
- IMKTA 11-26-2025
- IMNM 11-06-2025
- Dividend Yield
- IMKTA 0.85%
- IMNM N/A
- EPS Growth
- IMKTA N/A
- IMNM N/A
- EPS
- IMKTA 4.40
- IMNM N/A
- Revenue
- IMKTA $5,334,033,000.00
- IMNM $9,679,000.00
- Revenue This Year
- IMKTA N/A
- IMNM N/A
- Revenue Next Year
- IMKTA N/A
- IMNM $85.36
- P/E Ratio
- IMKTA $17.50
- IMNM N/A
- Revenue Growth
- IMKTA N/A
- IMNM N/A
- 52 Week Low
- IMKTA $58.92
- IMNM $5.15
- 52 Week High
- IMKTA $78.59
- IMNM $19.16
- Technical
- Relative Strength Index (RSI)
- IMKTA 67.91
- IMNM 62.73
- Support Level
- IMKTA $74.87
- IMNM $17.96
- Resistance Level
- IMKTA $75.09
- IMNM $19.16
- Average True Range (ATR)
- IMKTA 1.72
- IMNM 1.21
- MACD
- IMKTA 0.34
- IMNM 0.03
- Stochastic Oscillator
- IMKTA 82.08
- IMNM 86.50
About IMKTA Ingles Markets Incorporated
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.